Yonghe Medical Group Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Yonghe Medical Group.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Healthcare earnings growth | 18.5% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
Recent updates
Yonghe Medical Group Co., Ltd.'s (HKG:2279) Shares Leap 60% Yet They're Still Not Telling The Full Story
Sep 30
Is Yonghe Medical Group (HKG:2279) Using Debt Sensibly?
May 24It's Down 34% But Yonghe Medical Group Co., Ltd. (HKG:2279) Could Be Riskier Than It Looks
Mar 31Are Yonghe Medical Group Co., Ltd. (HKG:2279) Investors Paying Above The Intrinsic Value?
Oct 19The Consensus EPS Estimates For Yonghe Medical Group Co., Ltd. (HKG:2279) Just Fell Dramatically
Sep 08Is Yonghe Medical Group Co., Ltd. (HKG:2279) Expensive For A Reason? A Look At Its Intrinsic Value
Aug 19Yonghe Medical Group's (HKG:2279) Soft Earnings Don't Show The Whole Picture
Mar 31In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Yonghe Medical Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2024 | 1,850 | -453 | 0 | 82 | N/A |
| 3/31/2024 | 1,813 | -496 | -94 | 32 | N/A |
| 12/31/2023 | 1,777 | -538 | -188 | -17 | N/A |
| 9/30/2023 | 1,635 | -430 | -246 | -35 | N/A |
| 6/30/2023 | 1,492 | -322 | -304 | -54 | N/A |
| 3/31/2023 | 1,453 | -203 | -328 | -81 | N/A |
| 12/31/2022 | 1,413 | -84 | -352 | -109 | N/A |
| 9/30/2022 | 1,638 | 6 | -206 | 15 | N/A |
| 6/30/2022 | 1,863 | 95 | -59 | 139 | N/A |
| 3/31/2022 | 2,016 | 107 | 94 | 288 | N/A |
| 12/31/2021 | 2,169 | 118 | 247 | 437 | N/A |
| 9/30/2021 | 2,129 | 121 | 301 | 492 | N/A |
| 6/30/2021 | 2,090 | 125 | 355 | 546 | N/A |
| 3/31/2021 | 1,864 | 136 | 357 | 524 | N/A |
| 12/31/2020 | 1,638 | 147 | 359 | 502 | N/A |
| 12/31/2019 | 1,224 | 36 | 74 | 182 | N/A |
| 12/31/2018 | 934 | 54 | 58 | 195 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 2279's forecast earnings growth is above the savings rate (2.3%).
Earnings vs Market: Insufficient data to determine if 2279's earnings are forecast to grow faster than the Hong Kong market
High Growth Earnings: Insufficient data to determine if 2279's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 2279's revenue is forecast to grow faster than the Hong Kong market.
High Growth Revenue: Insufficient data to determine if 2279's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 2279's Return on Equity is forecast to be high in 3 years time